Abstract
The link between cancer, hypertension and anti-hypertensive drug treatment is controversial. Despite numerous studies looking either directly or indirectly at cancer and hypertension, the results are often conflicting and do little to answer the dominant questions of cause and effect. Also, the treatment of hypertension has continued to evolve, with newer therapies being made available including angiotensin- converting enzyme inhibitors. Whilst the potential link with cancer is thought to be small at worst, with the overall benefits of hypertension faroutweighing its negative impacts, the suggestion of a carcinogenic role for either hypertension or its treatment continues to be an emotive issue, and needs firm answers. In this review, we provide an overview establishing the strengths and weaknesses of the arguments presented and highlight possible pharmacophysiological pathways involved.
Keywords: Hypertension, anti-hypertensive, cancer
Current Pharmaceutical Design
Title: Hypertension, Anti-Hypertensive Therapy and Neoplasia
Volume: 13 Issue: 25
Author(s): Patrick K.Y. Goon, Paul S. Stonelake and Gregory Y.H. Lip
Affiliation:
Keywords: Hypertension, anti-hypertensive, cancer
Abstract: The link between cancer, hypertension and anti-hypertensive drug treatment is controversial. Despite numerous studies looking either directly or indirectly at cancer and hypertension, the results are often conflicting and do little to answer the dominant questions of cause and effect. Also, the treatment of hypertension has continued to evolve, with newer therapies being made available including angiotensin- converting enzyme inhibitors. Whilst the potential link with cancer is thought to be small at worst, with the overall benefits of hypertension faroutweighing its negative impacts, the suggestion of a carcinogenic role for either hypertension or its treatment continues to be an emotive issue, and needs firm answers. In this review, we provide an overview establishing the strengths and weaknesses of the arguments presented and highlight possible pharmacophysiological pathways involved.
Export Options
About this article
Cite this article as:
Goon K.Y. Patrick, Stonelake S. Paul and Lip Y.H. Gregory, Hypertension, Anti-Hypertensive Therapy and Neoplasia, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663073
DOI https://dx.doi.org/10.2174/138161207781663073 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design Definition of Postprandial Lipaemia
Current Vascular Pharmacology The Role of Exosomes and Exosome-derived microRNAs in Atherosclerosis
Current Pharmaceutical Design Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Insight on the Pathogenesis of Diabetic Nephropathy from the Study of Podocyte and Mesangial Cell Biology
Current Diabetes Reviews Novel Strategies in the Treatment of Pulmonary Arterial Hypertension
Current Drug Targets Potential Therapeutic Effects of Exogenous Ketone Supplementation for Type 2 Diabetes: A Review
Current Pharmaceutical Design Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension
Current Hypertension Reviews Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Genetic Variation of de novo Lipogenesis Pathway and Individual Sus-ceptibility to Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Design and Optimization of a Novel Spectrophotometric Method using Response Surface Methodology for the Determination of Los artan Potassium in Pharmaceuticals
Current Pharmaceutical Analysis Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms
Current Pharmaceutical Analysis Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Advances in Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)
Mini-Reviews in Medicinal Chemistry Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research